Document:

<PAGE>

                                                                     EXHIBIT 4.2

THIS CONVERTIBLE PROMISSORY NOTE (THIS "NOTE") AND THE SHARES OF COMMON STOCK
ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAW.
NEITHER THIS NOTE NOR SUCH SHARES OF COMMON STOCK NOR ANY INTEREST OR
PARTICIPATION HEREIN OR THEREIN MAY BE SOLD, ASSIGNED, MORTGAGED, PLEDGED,
HYPOTHECATED, ENCUMBERED OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE
ACT AND APPLICABLE STATE SECURITIES LAWS.

                              AETHLON MEDICAL, INC.
                           CONVERTIBLE PROMISSORY NOTE

$30,000.00                                                          MAY 16, 2005

         AETHLON MEDICAL, INC., a Nevada corporation (the "Company"), for value
received, hereby promises to pay to Fusion Capital Fund II, LLC or its assigns
(the "Holder"), in legal tender of the United States of America, the principal
sum of THIRTY THOUSAND DOLLARS ($30,000.00) on August 15, 2005 (the "Maturity
Date"), and to pay interest thereon at the rate of fifteen percent (15%) per
annum. Interest shall accrue daily, be compounded, and be computed on the basis
of a 360-day year and the number of actual days elapsed.

         This Convertible Promissory Note is the Convertible Promissory Note
referred to and issued pursuant to the terms of that certain Letter Agreement
dated as of the date hereof, by and between the Company and Holder ("Letter
Agreement").

         SECTION 1. TIME AND PLACE OF PAYMENT. (a) The entire unpaid principal
balance of this Note, together with any accrued and unpaid interest thereon,
shall be due and payable on the Maturity Date. Principal and interest on this
Note shall be paid by wire transfer of immediately available funds or by check
delivered to the Holder's registered address as it appears upon the books of the
Company. Upon the payment in full of this Note, the Holder shall immediately
surrender this Note to the Company at its executive offices.

         (b) Any payment made under this Note, whether upon acceleration, final
maturity or otherwise, shall be applied first to the payment of any accrued and
unpaid interest and the balance (if any) shall be applied on account of
principal.

         (c) Whenever any payment to be made under this Note shall be due on a
Saturday, Sunday or any day on which banks are required or authorized by law or
regulation to close in New York City (any other day being a "Business Day"),
such payment may be made on the next succeeding Business Day, and such extension
of time shall in such case not be included in the computation of interest
accrued.

<PAGE>

         (d) Notwithstanding any other provision of this Note, in the event that
any portion of the principal amount of this Note is converted into any shares of
the Company's Common Stock in accordance with the provisions of Section 3 below,
then no interest shall be payable on the portion so converted for the period
following the date of conversion.

         (e) From and after the Maturity Date or after the occurrence of an
Event of Default (as hereinafter defined) under this Note then the interest rate
under this Note shall be increased to twenty percent (20%) per annum and shall
be calculated in accordance with the terms of the Note.

         (f) In no event shall the Holder be entitled to convert this Note for a
number of Conversion Shares in excess of that number of Conversion Shares which,
upon giving effect to such conversion, would cause the aggregate number of
shares of Common Stock beneficially owned by the Holder to exceed 9.9% of the
outstanding shares of the Common Stock following such conversion. For purposes
of the foregoing proviso, the aggregate number of shares of Common Stock
beneficially owned by the Holder shall include the number of shares of Common
Stock issuable upon exercise of this Note with respect to which determination of
such proviso is being made, but shall exclude the shares of Common Stock which
would be issuable upon (i) conversion of the remaining outstanding Note balance
and accrued interest beneficially owned by the Holder and (ii) exercise or
conversion of the unexercised or unconverted portion of any other securities of
the Company beneficially owned by the Holder subject to a limitation on
conversion or exercise analogous to the limitation contained herein. Except as
set forth in the preceding sentence, for purposes of this paragraph, beneficial
ownership shall be calculated in accordance with Section 13(d) of the Securities
Exchange Act of 1934, as amended. The Holder may waive the foregoing limitation
by written notice to the Company upon not less than 61 days prior written notice
(with such waiver taking effect only upon the expiration of such 61 day notice
period).

         SECTION 2. PREPAYMENTS. At any time on or prior to the Maturity Date,
the Company shall have the right to prepay this Note, in whole or in part, on 10
days' advance notice to the Holder and subject to the right of the Holder to
convert in advance of such prepayment date and provided that on such prepayment
date, the Company will pay in respect of the redeemed Note cash equal to the
face amount plus accrued interest on the Note (or portion thereof) redeemed. At
any time after the Maturity Date, the Company shall have the right to repay this
Note, in whole or in part, on 10 days' advance notice to the Holder and subject
to the right of the Holder to convert in advance of such repayment date and
provided that on such repayment date, the Company will pay in respect of the
redeemed Note cash equal to 150% of the face amount plus accrued interest on the
Note (or portion thereof).

         SECTION 3. CONVERSION.

                                       2
<PAGE>

         (a) The Holder shall have the right from time to time, at its option,
at any time to convert the principal amount (or any portion thereof) of this
Note, together with all accrued interest thereon in accordance with the
provisions of and upon satisfaction of the conditions contained in this Note,
into fully paid and non-assessable shares of the Company's common stock (the
"Conversion Shares") at a conversion price (the "Conversion Price") equal to
$0.20 per share for any conversion occurring on or prior to the Maturity Date,
or at price equal to the lesser of (i) 75% of the average of the three (3)
lowest closing sale prices of the common shares during the twelve (12) trading
days prior to the submission of a conversion notice or (ii) $0.20 per share, for
any conversions occurring after the Maturity Date.

         (b) The Holder's conversion right set forth in this Section may be
exercised at any time and from time to time but prior to payment in full of the
principal amount of and accrued interest on this Note.

         (c) The Holder may exercise the right to convert all or any portion of
the principal amount and accrue interest of this Note by delivery of (i) this
Note and (ii) a completed conversion notice on a Business Day to the Company's
principal executive offices. Such conversion shall be deemed to have been made
immediately prior to the close of business on the Business Day of such delivery
a conversion notice (the "Conversion Date"), and the Holder shall be treated for
all purposes as the record holder of the shares of Common Stock into which this
Note is converted as of such date.

         (d) As promptly as practicable after the conversion of this Note, the
Company at its expense shall issue and deliver to the Holder of this Note a
stock certificate or certificates representing the number of Conversion Shares
into which this Note has been converted.

         (e) Upon conversion of the entire principal amount and accrued interest
of this Note and the delivery of the items set forth in Section 3(d), except as
otherwise provided in Section 15 of this Note, the Company shall be forever
released from all of its obligations and liabilities under this Note.

         (f) If, prior to the Conversion Date, the Company shall (i) pay a stock
dividend or make a distribution to all holders of Common Stock in shares of its
Common Stock, (ii) subdivide its outstanding shares of Common Stock, (iii)
combine its outstanding shares of Common Stock into a smaller number of shares,
(iv) issue by reorganization, reclassification or recapitalization of its shares
of Common Stock any shares of capital stock of the Company, or (v) take any
other action which has the effect of diluting the number of Conversion Shares
issuable upon conversion of this Note, the number of Conversion Shares shall be
equitably and proportionately increased or decreased, as the case may be.

         (g) The Company agrees that the Holder shall retain the right to
convert even if the Company indicates its willingness to repay the loan.

         SECTION 4. RESERVATION OF STOCK, ETC. The Company covenants and agrees
that it will at all times have authorized, reserve and keep available, solely
for the purpose of effecting the conversion of this Note such number of its
shares of such Common Stock as shall from time to time be sufficient to effect

                                       3
<PAGE>

the conversion of this Note in full. The Company further covenants and agrees
that this Note is, and any Notes issued in substitution for or replacement of
this Note and all Conversion Shares, will upon issuance be duly authorized and
validly issued and, in the case of Conversion Shares, upon issuance will be
fully paid and non-assessable and free from all preemptive rights of any
stockholder, and from all taxes, liens and charges with respect to the issue
thereof (other than transfer taxes) and, if the Common Stock of the Company is
then listed on any national securities exchanges (as defined in the Exchange Act
of 1934, as amended (the "Exchange Act")) or quoted on NASDAQ, shall be, subject
to the restrictions set forth in Section 5, duly listed or quoted thereon, as
the case may be. In the event that the number of authorized but unissued shares
of such Common Stock shall not be sufficient to effect the conversion of the
entire outstanding principal amount of this Note, then in addition to such other
remedies as shall be available to the Holder, the Company shall promptly take
such corporate action as may be necessary to increase its authorized but
unissued shares of such Common Stock to such number of shares as shall be
sufficient for such purpose.

         SECTION 5. TRANSFER RESTRICTIONS; EXEMPTION FROM REGISTRATION.

(a) The holder of this Note is entitled to certain registration rights with
respect to the Conversion Shares issuable upon conversion thereof. Said
registration rights are set forth in the Letter Agreement by and between the
Holder and the Company. This Note may not be transferred except upon
satisfaction of all of the requirements of the Act and applicable state
securities laws. Without limiting the generality of the foregoing, the Holder
agrees that (i) this Note and the Conversion Shares have not been registered
under the Act and may not be sold or transferred without registration under the
Act or unless an exemption from such registration is available; (ii) the Holder
has acquired this Note and will acquire the Conversion Shares for its own
account for investment purposes only and not with a view toward resale or
distribution; and (iii) if the registration statement contemplated in the Letter
Agreement is not effective at the time any Conversion Shares are issued to
Holder upon conversion under this Note, and the Conversion Shares are not exempt
from registration under Rule 144, then the Conversion Shares shall be inscribed
with the following legend:

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE
SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE,
SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS, OR AN OPINION OF HOLDER'S COUNSEL, IN A
CUSTOMARY FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE
STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

                                       4
<PAGE>

         (b) If an opinion of counsel of Holder provides that registration is
not required for the proposed conversion or transfer of this Note or the
proposed transfer of the Conversion Shares and that the proposed conversion or
transfer in the absence of registration would require the Company to take any
action including executing and filing forms or other documents with the
Securities and Exchange Commission (the "SEC") or any state securities agency,
or delivering to the Holder any form or document in order to establish the right
of the Holder to effectuate the proposed conversion or transfer, the Company
agrees promptly, at its expense, to take any such action; and provided, further,
that the Company will reimburse the Holder in full for any expenses (including
but not limited to the fees and disbursements of such counsel, but excluding
brokers' commissions) incurred by the Holder or owner of Conversion Shares on
his, her or its behalf in connection with such conversion or transfer of the
Note or transfer of Conversion Shares.

         SECTION 6.  RULE 144

         In the event that the Company (a) has or registers a class of
securities under Section 12 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act") or (b) has or commences to file reports under Section 13 or
15(d) of the Exchange Act, then at the request of any Holder who proposes to
sell securities in compliance with Rule 144 of the SEC, the Company will (i)
forthwith furnish to such holder a written statement of compliance with the
filing requirements of the SEC as set forth in Rule 144, as such rules may be
amended from time to time and (ii) make available to the public and such holders
such information and take such other action as is requested by the holder as
will enable the holder to make sales pursuant to Rule 144.

         SECTION 7. EVENTS OF DEFAULT. If any of the following events shall
occur (herein individually referred to as an "Event of Default"), Holder may
declare the entire unpaid principal and accrued interest on this Note
immediately due and payable, by a notice in writing to the Company.

         (a) Any default by the Company under any provision of this Note or if
the Company breaches or fails to perform or observe any covenant,
representation, warranty or agreement contained in this Note; or

         (b) Any default by the Company under any provision of any other
agreement or contract entered into between the Company and Holder ("Other
Agreements") or if the Company breaches or fails to perform or observe any
covenant, representation, warranty or agreement contained in any Other
Agreements; or

         (c) The institution by the Company of proceedings to be adjudicated a
bankrupt or insolvent, or the consent by it to institution of bankruptcy or
insolvency proceedings against it or the filing by it of a petition or answer or
consent seeking reorganization or release under the Federal bankruptcy laws, or
any other applicable Federal or state law, or the consent by it to the filing of
any such petition or the appointment of a receiver, liquidator, assignee,
trustee, or other similar official, of the Company, or of any substantial part
of its property, or the making by it of an assignment for the benefit of
creditors, or the admission by it in writing of its inability to pay its debts
generally as they become due or the taking of corporate action by the Company in
furtherance of any such action; or

                                       5
<PAGE>

         (d) If, within 30 days after the commencement of an action against the
Company seeking bankruptcy, insolvency, reorganization, liquidation, dissolution
or similar relief under any present or future statute, law or regulation, such
action shall not have been dismissed or all orders or proceedings thereunder
affecting the operations or the business of the Company stayed, or if the stay
or any such order or proceeding shall thereafter bet set aside, or if, within 30
days after the appointment without the consent or acquiescence of the Company of
any trustee, receiver or liquidator of the Company or of all or any substantial
part of the properties of the Company, such appointment shall not have been
vacated.

         SECTION 8. TAXES, COSTS AND EXPENSES. The Company covenants and agrees
that it will pay when due and payable any and all federal, state and local taxes
(other than income taxes) and any other costs and expenses which may be payable
in respect of the preparation, issuance, delivery, conversion, surrender or
transfer of this Note pursuant to the terms of this Note or the issuance of any
Conversion Shares as a result thereof. If any suit or action is instituted or
attorneys employed to collect or enforce this Note or any part thereof, the
Company promises and agrees to pay on demand all costs and expenses of
collection, including reasonable attorneys' fees and court costs.

         SECTION 9. LOSS OF NOTE. Upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of
this Note, and (in the case of loss, theft or destruction) of indemnification in
form and substance acceptable to the Company in its reasonable discretion, and
upon surrender and cancellation of this Note, if mutilated, the Company shall
execute and deliver a new Note of like tenor and date.

         SECTION 10. ENTIRE AGREEMENT. With the exception of the Registration
Rights Agreement and Common Stock Purchase Agreement between the parties dated
as of May 20, 2004, this Note and the Letter Agreement each of even date
represent the entire agreement and understanding between the parties concerning
the subject matter hereof and supersede all prior and contemporaneous
agreements, understandings, representations and warranties with respect thereto.

         SECTION 11. BINDING EFFECT; NO THIRD PARTY BENEFICIARIES. All
provisions of this Note shall be binding upon and inure to the benefit of the
parties and their respective heirs, legatees, executors, administrators, legal
representatives, successors, and permitted transferees and assigns. No person
other than the Holder and the Company shall have any legal or equitable right,
remedy or claim under or in respect of, this Note.

         SECTION 12. AMENDMENT AND WAIVERS. This Note may be amended, changed or
modified only by a written instrument executed by the Company and the Holder of
this Note. Any waiver of any breach of any of the terms of this Note, and any
consent required or permitted to be given hereunder, shall be effective if in
writing and executed by or on behalf of the Holder of this Note. No waiver of
any breach nor consent to any transaction shall be deemed a waiver of or consent
to any other or subsequent breach or transaction.

                                       6
<PAGE>

         SECTION 13. WAIVER OF PRESENTMENT, ETC. The Company hereby waives
presentment for payment, demand, notice of non-payment, protest and notice of
protest and hereby agrees to all extensions and renewals of this Note, without
notice.

         SECTION 14. GOVERNING LAW; JURISDICTION; JURY TRIAL. The corporate laws
of the State of Nevada shall govern all issues concerning the relative rights of
the Company and its shareholders. All other questions concerning the
construction, validity, enforcement and interpretation of this Note and the
Letter Agreement shall be governed by the internal laws of the State of
Illinois, without giving effect to any choice of law or conflict of law
provision or rule (whether of the State of Illinois or any other jurisdictions)
that would cause the application of the laws of any jurisdictions other than the
State of Illinois. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of Chicago, for
the adjudication of any dispute hereunder or under the Letter Agreement or in
connection herewith or therewith, or with any transaction contemplated hereby or
discussed herein, or in any manner arising in connection with or related to the
transactions contemplated hereby or involving the parties hereto whether at law
or equity and under any contract, tort or any other claim whatsoever and hereby
irrevocably waives, and agrees not to assert in any suit, action or proceeding,
any claim that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is brought in an inconvenient forum
or that the venue of such suit, action or proceeding is improper. Each party
hereby irrevocably waives personal service of process and consents to process
being served in any such suit, action or proceeding by mailing or faxing a copy
thereof to such party at the address for such notices as listed on the signature
page hereto and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.
EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE, AND AGREES NOT TO
REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN
CONNECTION HEREWITH OR ARISING OUT OF THIS NOTE OR ANY TRANSACTION CONTEMPLATED
HEREBY.

         SECTION 15. REPRESENTATIONS AND WARRANTIES TO SURVIVE CLOSING. All
representations, warranties and covenants contained herein shall survive the
execution and delivery of this Note and the issuance of any Conversion Shares
upon the conversion hereof.

         SECTION 16. SEVERABILITY. In the event that any court or any
governmental authority or agency declares all or any part of any Section of this
Note to be unlawful or invalid, such unlawfulness or invalidity shall not serve
to invalidate any other Section of this Note, and in the event that only a
portion of any Section is so declared to be unlawful or invalid, such
unlawfulness or invalidity shall not serve to invalidate the balance of such
Section.

                                       7
<PAGE>

         SECTION 17. HEADINGS. The headings used in this Note are used for
convenience only and are not to be considered in construing or interpreting this
Note.

         IN WITNESS WHEREOF, the Company has caused this Note to be signed this
day by a duly authorized officer.

AETHLON MEDICAL, INC.
By:________________________
Name:_____________________
Title:______________________

Company Notice Information:
---------------------------

Aethlon Medical, Inc.
7825 Fay Avenue, Suite 200
La Jolla, CA 92037
Telephone:         858-456-5777
Facsimile:         858-456-4690
Attention:         James Joyce

With a copy to:
Richardson & Patel, LLP
10900 Wilshire Blvd., Suite 500
Los Angeles, CA 90404
Telephone:         (310) 208-1182
Facsimile:         (310) 208-1154
Attention:         Nimish Patel

Holder Notice Information:
--------------------------

Fusion Capital Fund II, LLC
222 Merchandise Mart Plaza, Suite 9-112
Chicago, IL 60654
Telephone:        312-644-6644
Facsimile:        312-644-6244
Attention:        Steven G. Martin

                                       8
<PAGE>

                                    EXHIBIT A

                                CONVERSION NOTICE

                (To be signed only upon conversion of this Note)

TO:     AETHLON MEDICAL, INC.

The undersigned, the registered holder of the Convertible Promissory Note (the
"Note") of AETHLON MEDICAL, INC. (the "Company"), hereby surrenders the Note for
conversion into shares of Common Stock of the Company ("Common Stock") to the
extent of $_______ unpaid principal amount of the Note and $_______ unpaid
accrued interest due under the Note, all in accordance with the provisions of
such Note. The undersigned requests (i) that a certificate representing shares
of Common Stock, bearing the appropriate legends, be issued to the undersigned,
and (ii) if the unpaid principal amount so converted is less than the entire
unpaid principal amount of the Note, that a new substitute note representing the
portion of said unpaid principal amount that is not so converted be issued in
accordance with the provisions of the Note.

Dated:  ___________________________________________________
          (Signature and name of the registered holder)

                                       9<PAGE>

                                                                     Exhibit 4.3

THIS WARRANT (THIS "WARRANT") HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE "ACT"), OR ANY STATE SECURITIES LAW. NEITHER THIS
WARRANT NOR ANY WARRANT SHARES ISSUABLE UPON EXERCISE HEREOF NOR ANY INTEREST OR
PARTICIPATION HEREIN OR THEREIN MAY BE SOLD, ASSIGNED, MORTGAGED, PLEDGED,
HYPOTHECATED, ENCUMBERED OR OTHERWISE TRANSFERRED EXCEPT IN COMPLIANCE WITH THE
ACT AND APPLICABLE STATE SECURITIES LAWS.

                              AETHLON MEDICAL, INC.

                                     WARRANT
                        Original Issue Date: May 16, 2005

         This Warrant is issued in connection with and pursuant to that certain
Letter Agreement (the "LETTER AGREEMENT") dated as of the date hereof, by and
between AETHLON MEDICAL, INC., a Nevada corporation (the "Company") and FUSION
CAPITAL FUND II, LLC (the "Buyer").

         FOR VALUE RECEIVED, the Buyer, the registered holder hereof, or its
permitted assigns (the "Holder"), is entitled to purchase from the Company,
during the period specified in this Warrant, 300,000 fully paid and
non-assessable shares (subject to adjustment as hereinafter provided) of Common
Stock (the "WARRANT SHARES"), of the Company at the purchase price per share
provided in Section 1.2 of this Warrant (the "WARRANT EXERCISE PRICE"), all
subject to the terms and conditions set forth in this Warrant. Capitalized terms
used herein and not otherwise defined herein shall have the respective meanings
set forth in the Common Stock Purchase Agreement by and between the parties
hereto, dated as of May 20, 2004 (as amended, restated, supplemented or
otherwise modified from time to time, the "PURCHASE AGREEMENT").

SECTION 1.        PERIOD FOR EXERCISE AND EXERCISE PRICE.

         1.1 PERIOD FOR EXERCISE. The right to purchase shares of Warrant Shares
represented by this Warrant shall be immediately exercisable, and shall expire
at 5:00 p.m., Chicago local time, May 16, 2010 (the "EXPIRATION DATE"). From and
after the Expiration Date this Warrant shall be null and void and of no further
force or effect whatsoever.

         1.2 WARRANT EXERCISE PRICE. The Warrant Exercise Price per share of
Warrant Shares shall be $0.25 per share (subject to adjustment as hereinafter
provided).

SECTION 2.        EXERCISE OF WARRANT.

<PAGE>

         2.1 MANNER OF EXERCISE. The Holder may exercise this Warrant, in whole
or in part, immediately, but not after the Expiration Date, during normal
business hours on any Trading Day by surrendering this Warrant to the Company at
the principal office of the Company, accompanied by a Warrant Exercise Form in
substantially the form annexed hereto duly executed by the Buyer and by payment
of the Warrant Exercise Price for the number of shares of Warrant Shares for
which this Warrant is then exercisable, either (i) in immediately available
funds, (ii) by delivery of an instrument evidencing indebtedness owing by the
Company to the Holder in the appropriate amount, (iii) by authorizing the
Company to retain shares of Common Stock which would otherwise be issuable upon
exercise of this Warrant in accordance with Section 2.4 hereof or (iv) in a
combination of (i), (ii) or (iii) above, provided, however, that in no event
shall the Holder be entitled to exercise this Warrant for a number of Warrant
Shares in excess of that number of Warrant Shares which, upon giving effect to
such exercise, would cause the aggregate number of shares of Common Stock
beneficially owned by the Holder to exceed 9.9% of the outstanding shares of the
Common Stock following such exercise. For purposes of the foregoing proviso, the
aggregate number of shares of Common Stock beneficially owned by the Holder
shall include the number of shares of Common Stock issuable upon exercise of
this Warrant with respect to which determination of such proviso is being made,
but shall exclude the shares of Common Stock which would be issuable upon (i)
exercise of the remaining, unexercised Warrants beneficially owned by the Holder
and (ii) exercise or conversion of the unexercised or unconverted portion of any
other securities of the Company beneficially owned by the Holder subject to a
limitation on conversion or exercise analogous to the limitation contained
herein. Except as set forth in the preceding sentence, for purposes of this
paragraph, beneficial ownership shall be calculated in accordance with Section
13(d) of the Securities Exchange Act of 1934, as amended. The Holder may waive
the foregoing limitation by written notice to the Company upon not less than 61
days prior written notice (with such waiver taking effect only upon the
expiration of such 61 day notice period).

         2.2 WHEN EXERCISE EFFECTIVE. Each exercise of this Warrant shall be
deemed to have been effected on the day on which all requirements of Section 2.1
shall have been met with respect to such exercise. At such time the person in
whose name any certificate for shares of Warrant Shares shall be issuable upon
such exercise shall be deemed for all corporate purposes to have become the
Holder of record of such shares, regardless of the actual delivery of
certificates evidencing such shares.

         2.3 DELIVERY OF STOCK CERTIFICATES. As soon as practicable after each
exercise of this Warrant, and in any event no later than 3 days after such
exercise, the Company at its expense will issue Warrant Shares via credit to the
Buyer's account with DTC for the number of Warrant Shares to which such Buyer is
entitled upon such Buyer's submission of the applicable Warrant Exercise Form
or, if the Transfer Agent is not participating in The DTC Fast Automated
Securities Transfer Program and DWAC system, issue and surrender to the address
as specified in the Warrant Exercise Form, a certificate, registered in the name
of the Buyer or its designee, for the number of shares of Common Stock to which
the Buyer shall be entitled to upon such exercise.

                                       2
<PAGE>

         2.4 CASHLESS EXERCISE. At any such time as the Warrant Shares are not
registered for sale pursuant to a registration statement that is effective and
current and available for resale pursuant to the Securities Act of 1933, as
amended, the Holder may, by providing notice thereof to the Company along with
the Warrant Exercise Form, elect to exercise the Warrant for a number of Warrant
Shares determined in accordance with the following formula:

               X = Y(A-B)
                   ------
                      A

               Where:

               X = The number of Warrant Shares to be issued to the Holder.
               Y = The number of Warrant Shares purchasable under this Warrant
               (at the date of such exercise).
               A = The fair market value of one share of Common Stock (or
               other security for which the Warrant is then exercisable at
               the date of such exercise).
               B = Exercise Price (as adjusted to the date of such exercise).

For purposes of this Section 2.4, the "fair market value" per share shall be the
closing sale price of the Common Stock for the three Trading Days immediately
prior to the notice of exercise of the Warrant.

         SECTION 3. ADJUSTMENT OF PURCHASE PRICE AND NUMBER OF SHARES. The
Warrant Exercise Price and the kind of securities issuable upon exercise of the
Warrant shall be adjusted from time to time as follows:

         3.1 SUBDIVISION OR COMBINATION OF SHARES (STOCK SPLITS). If the Company
at any time effects a subdivision or combination of the outstanding Common Stock
(through a stock split or otherwise), the number of shares of Warrant Shares
shall be increased, in the case of a subdivision, or the number of shares of
Warrant Shares shall be decreased, in the case of a combination, in the same
proportions as the Common Stock is subdivided or combined, in each case
effective automatically upon, and simultaneously with, the effectiveness of the
subdivision or combination which gives rise to the adjustment.

         3.2 STOCK DIVIDENDS. If the Company at any time pays a dividend, or
makes any other distribution, to holders of Common Stock payable in shares of
Common Stock, or fixes a record date for the determination of holders of Common
Stock entitled to receive a dividend or other distribution payable in shares of
Common Stock, then the number of shares of Warrant Shares in effect immediately
prior to such action shall be proportionately increased so that the Holder
hereof may receive upon exercise of the Warrant the aggregate number of shares

                                       3
<PAGE>

of Common Stock which he or it would have owned immediately following such
action if the Warrant had been exercised immediately prior to such action. The
adjustment shall become effective immediately as of the date the Company shall
take a record of the holders of its Common Stock for the purpose of receiving
such dividend or distribution (or if no such record is taken, as of the
effectiveness of such dividend or distribution).

         3.3 RECLASSIFICATION, CONSOLIDATION OR MERGER. If at any time, as a
result of:

                  (a) a capital reorganization or reclassification (other than a
         subdivision, combination or dividend provided for elsewhere in this
         Section 3), or

                  (b) a merger or consolidation of the Company with another
         corporation (whether or not the Company is the surviving corporation),

the Common Stock issuable upon exercise of the Warrants shall be changed into or
exchanged for the same or a different number of shares of any class or classes
of stock of the Company or any other corporation, or other securities
convertible into such shares, then, as a part of such reorganization,
reclassification, merger or consolidation, appropriate adjustments shall be made
in the terms of the Warrants (or of any securities into which the Warrants are
exercised or for which the Warrants are exchanged), so that:

         (y) the Holders of Warrants or of such substitute securities shall
thereafter be entitled to receive, upon exercise of the Warrants or of such
substitute securities, the kind and amount of shares of stock, other securities,
money and property which such Holders would have received at the time of such
capital reorganization, reclassification, merger, or consolidation, if such
Holders had exercised their Warrants immediately prior to such capital
reorganization, reclassification, merger, or consolidation, and

         (z) the Warrants or such substitute securities shall thereafter be
adjusted on terms as nearly equivalent as may be practicable to the adjustments
theretofore provided in this Section 3.3.

No consolidation or merger in which the Company is not the surviving corporation
shall be consummated unless the surviving corporation shall agree, in writing,
to the provisions of this Section 3.3. The provisions of this Section 3.3 shall
similarly apply to successive capital reorganizations, reclassifications,
mergers and consolidations.

         3.4 OTHER ACTION AFFECTING COMMON STOCK. If at any time the Company
takes any action affecting its Common Stock, other than an action described in
any of Sections 3.1 - 3.3 which, in the opinion of the Board of Directors of the
Company (the "BOARD"), would have an adverse effect upon the exercise rights of
the Warrants, the Warrant Exercise Price or the kind of securities issuable upon
exercise of the Warrants, or both, shall be adjusted in such manner and at such
time as the Board may in good faith determine to be equitable in the
circumstances; provided, however, that the purpose of this Section is to prevent
the Company from taking any action which has the effect of diluting the number
of shares of Warrant Shares issuable upon exercise of this Warrant.

                                       4
<PAGE>

         3.5 NOTICE OF ADJUSTMENT EVENTS. Whenever the Company contemplates the
occurrence of an event which would give rise to adjustments under this Section
3, the Company shall mail to each Warrant Holder, at least 20 days prior to the
record date with respect to such event or, if no record date shall be
established, at least 20 days prior to such event, a notice specifying (i) the
nature of the contemplated event, and (ii) the date on which any such record is
to be taken for the purpose of such event, and (iii) the date on which such
event is expected to become effective, and (iv) the time, if any is to be fixed,
when the holders of record of Common Stock (or other securities) shall be
entitled to exchange their shares of Common Stock (or other securities) for
securities or other property deliverable in connection with such event.

         3.6 NOTICE OF ADJUSTMENTS. Whenever the kind or number of securities
issuable upon exercise of the Warrants, or both, shall be adjusted pursuant to
Section 3, the Company shall deliver a certificate signed by its Chief Executive
Officer and by its Chief Financial Officer, setting forth, in reasonable detail,
the event requiring the adjustment, the amount of the adjustment, the method by
which such adjustment was calculated (including a description of the basis on
which the Board made any determination hereunder), and the Warrant Exercise
Price and the kind of securities issuable upon exercise of the Warrants after
giving effect to such adjustment, and shall cause copies of such certificate to
be mailed (by first class mail postage prepaid) to each Warrant Holder promptly
after each adjustment.

         SECTION 4. RESERVATION OF STOCK, ETC. The Company covenants and agrees
that it will at all times have authorized, reserve and keep available, solely
for issuance and delivery upon the exercise of this Warrant, the number of
shares of Warrant Shares from time to time issuable upon the exercise of this
Warrant. The Company further covenants and agrees that this Warrant is, and any
Warrants issued in substitution for or replacement of this Warrant and all
Warrant Shares, will upon issuance be duly authorized and validly issued and, in
the case of Warrant Shares, upon issuance will be fully paid and non-assessable
and free from all preemptive rights of any stockholder, and from all taxes,
liens and charges with respect to the issue thereof (other than transfer taxes)
and, if the Common Stock of the Company is then listed on any national
securities exchanges (as defined in the Exchange Act of 1934, as amended (the
"EXCHANGE ACT")) or quoted on NASDAQ, shall be, subject to the restrictions set
forth in Section 5, duly listed or quoted thereon, as the case may be. In the
event that the number of authorized but unissued shares of such Common Stock
shall not be sufficient to effect the exercise of this entire Warrant into
Warrant Shares, then in addition to such other remedies as shall be available to
the Holder of this Warrant, the Company shall promptly take such corporate
action as may be necessary to increase its authorized but unissued shares of
such Common Stock to such number of shares as shall be sufficient for such
purpose.

                                       5
<PAGE>

SECTION 5.        OWNERSHIP, TRANSFER AND SUBSTITUTION OF WARRANTS.

         5.1 OWNERSHIP OF WARRANTS. The Company may treat the person in whose
name any Warrant is registered on the register kept at the principal office of
the Company as the owner and Holder thereof for all purposes, notwithstanding
any notice to the contrary, but in all events recognizing any transfers made in
accordance with the terms of this Warrant.

         5.2 TRANSFER AND EXCHANGE OF WARRANTS. Upon the surrender of any
Warrant, properly endorsed, for registration of transfer or for exchange at the
principal office of the Company, the Company at its expense will execute and
deliver to the Holder thereof, upon the order of such Holder, a new Warrant or
Warrants of like tenor, in the name of such Holder or as such Holder may direct,
for such number of shares with respect to each such Warrant, the aggregate
number of shares in any event not to exceed the number of shares for which the
Warrant so surrendered had not been exercised.

         5.3 REGISTRATION RIGHTS. THE HOLDER OF THIS WARRANT IS ENTITLED TO
CERTAIN REGISTRATION RIGHTS WITH RESPECT TO THE WARRANT SHARES ISSUABLE UPON
EXERCISE THEREOF. If the registration statement contemplated in the Letter
Agreement is not effective at the time of any issuance and the shares are not
exempt from registration under Rule 144, the Warrant Shares shall be issued in
certificated form and shall bear the following restrictive legend:

         THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
         UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
         SECURITIES LAWS. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND
         MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE
         ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER
         THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
         LAWS, OR AN OPINION OF HOLDER'S COUNSEL, IN A CUSTOMARY FORM, THAT
         REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE
         SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

         5.4 EXEMPTION FROM REGISTRATION. If an opinion of Buyer's counsel
provides that registration is not required for the proposed exercise or transfer
of this Warrant or the proposed transfer of the Warrant Shares and that the
proposed exercise or transfer in the absence of registration would require the
Company to take any action including executing and filing forms or other
documents with the Securities and Exchange Commission (the "SEC") or any state
securities agency, or delivering to the Holder any form or document in order to
establish the right of the Holder to effectuate the proposed exercise or
transfer, the Company agrees promptly, at its expense, to take any such action;
and provided, further, that the Company will reimburse the Holder in full for
any expenses (including but not limited to ththe fees and disbursements of such
counsel, but excluding brokers' commissions) incurred by the Holder or owner of
Warrant Shares on his, her or its behalf in connection with such exercise or
transfer of the Warrant or transfer of Warrant Shares.

                                       6
<PAGE>

SECTION 6. NO RIGHTS OR LIABILITIES AS SHAREHOLDER. Nothing contained in this
Warrant shall be construed as conferring upon the Holder hereof any rights as a
shareholder of the Company or as imposing any liabilities on such holder to
purchase any securities or as a shareholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.

SECTION 7. RULE 144 SALES. At the request of any Holder who proposes to sell
securities in compliance with Rule 144 of the SEC, the Company will (i)
forthwith furnish to such Holder a written statement of compliance with the
filing requirements of the SEC as set forth in Rule 144, as such rules may be
amended from time to time and (ii) make available to the public and such Holder
such information as will enable the Holder to make sales pursuant to Rule 144.

SECTION 8.        MISCELLANEOUS.

         8.1 AMENDMENT AND WAIVER. This Warrant may be amended with, and only
with, the written consent of the Company and the Holder. Any waiver of any term,
covenant, agreement or condition contained in this Warrant shall not be deemed a
waiver of any other term, covenant, agreement or condition, and any waiver of
any default in any such term, covenant, agreement or condition shall not be
deemed a waiver of any later default thereof or of any default of any other
term, covenant, agreement or condition.

         8.2 REPRESENTATIONS AND WARRANTIES TO SURVIVE CLOSING. All
representations, warranties and covenants contained herein shall survive the
execution and delivery of this Warrant and the issuance of any Warrant Shares
upon the exercise hereof.

         8.3 SEVERABILITY. In the event that any court or any governmental
authority or agency declares all or any part of any Section of this Warrant to
be unlawful or invalid, such unlawfulness or invalidity shall not serve to
invalidate any other Section of this Warrant, and in the event that only a
portion of any Section is so declared to be unlawful or invalid, such
unlawfulness or invalidity shall not serve to invalidate the balance of such
Section.

         8.4 BINDING EFFECT; NO THIRD PARTY BENEFICIARIES. All provisions of
this Warrant shall be binding upon and inure to the benefit of the parties and
their respective heirs, legatees, executors, administrators, legal
representatives, successors, and permitted transferees and assigns. No person
other than the holder of this Warrant and the Company shall have any legal or
equitable right, remedy or claim under or in respect of, this Warrant.

                                       7
<PAGE>

         8.5 NOTICES. Any notices, consents, waivers or other communications
required or permitted to be given under the terms of this Warrant must be in
writing and will be deemed to have been delivered: (i) upon receipt, when
delivered personally; (ii) upon receipt, when sent by facsimile (provided
confirmation of transmission is mechanically or electronically generated and
kept on file by the sending party); or (iii) one Trading Day after deposit with
a nationally recognized overnight delivery service, in each case properly
addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be:

         If to the Company:
                  Aethlon Medical, Inc.
                  7825 Fay Avenue, Suite 200
                  La Jolla, CA 92037
                  Telephone:        858-456-5777
                  Facsimile:        858-456-4690
                  Attention:        James Joyce

         With a copy to:
                  Richardson & Patel, LLP
                  10900 Wilshire Blvd., Suite 500
                  Los Angeles, CA 90404
                  Telephone:        (310) 208-1182
                  Facsimile:          (310) 208-1154
                  Attention:         Nimish Patel, Esq

         If to the Buyer:
                  Fusion Capital Fund II, LLC
                  222 Merchandise Mart Plaza, Suite 9-112
                  Chicago, IL 60654
                  Telephone:        312-644-6644
                  Facsimile:        312-644-6244
                  Attention:        Steven G. Martin

         If to the Transfer Agent:
                  Computershare Trust Company
                  350 Indiana Street, #800
                  Golden, CO 80401
                  Telephone:        (303) 262-0600
                  Facsimile:        (303) 262-0700
                  Attention:

or at such other address and/or facsimile number and/or to the attention of such
other person as the recipient party has specified by written notice given to
each other party three (3) Trading Days prior to the effectiveness of such
change. Written confirmation of receipt (A) given by the recipient of such
notice, consent, waiver or other communication, (B) mechanically or
electronically generated by the sender's facsimile machine containing the time,
date, and recipient facsimile number or (C) provided by a nationally recognized
overnight delivery service, shall be rebuttable evidence of personal service,
receipt by facsimile or receipt from a nationally recognized overnight delivery
service in accordance with clause (i), (ii) or (iii) above, respectively.

                                       8
<PAGE>

         8.6 TAXES, COSTS AND EXPENSES. The Company covenants and agrees that it
will pay when due and payable any and all federal, state and local taxes (other
than income taxes) and any other costs and expenses which may be payable in
respect of the preparation, issuance, delivery, exercise, surrender or transfer
of this Warrant pursuant to the terms of this Warrant or the issuance of any
shares of Warrant Shares as a result thereof. If any suit or action is
instituted or attorneys employed to enforce this Warrant or any part thereof,
the Company promises and agrees to pay all costs and expenses associated
therewith, including reasonable attorneys' fees and court costs.

         8.7 GOVERNING LAW; JURISDICTION; JURY TRIAL. The corporate laws of the
State of Nevada shall govern all issues concerning the relative rights of the
Company and its shareholders. All other questions concerning the construction,
validity, enforcement and interpretation of this Warrant shall be governed by
the internal laws of the State of Illinois, without giving effect to any choice
of law or conflict of law provision or rule (whether of the State of Illinois or
any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of Illinois. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in
the City of Chicago, for the adjudication of any dispute hereunder or under the
other Transaction Documents or in connection herewith or therewith, or with any
transaction contemplated hereby or discussed herein, or in any manner arising in
connection with or related to the transactions contemplated hereby or involving
the parties hereto whether at law or equity and under any contract, tort or any
other claim whatsoever and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such suit, action or proceeding is
brought in an inconvenient forum or that the venue of such suit, action or
proceeding is improper. Each party hereby irrevocably waives personal service of
process and consents to process being served in any such suit, action or
proceeding by mailing a copy thereof to such party at the address for such
notices to it under this Warrant and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any
manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY
HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY
DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR ARISING OUT OF THIS WARRANT OR
ANY TRANSACTION CONTEMPLATED HEREBY.

         8.8 LOSS OF WARRANT. Upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this
Warrant, and (in the case of loss, theft or destruction) of indemnification in
form and substance acceptable to the Company in its reasonable discretion, and
upon surrender and cancellation of this Warrant, if mutilated, the Company shall
execute and deliver a new Warrant of like tenor and date.

                                       9
<PAGE>

         8.9 ENTIRE AGREEMENT. With the exception of the Registration Rights
Agreement and Common Stock Purchase Agreement between the parties dated as of
May 20, 2004, this Warrant and the Letter Agreement of even date herewith
represent the entire agreement and understanding between the parties concerning
the subject matter hereof and supercede all prior and contemporaneous
agreements, understandings, representations and warranties with respect thereto.

         8.10 HEADINGS. The headings used herein are used for convenience only
and are not to be considered in construing or interpreting this Warrant.

                                                     COMPANY:

                                                 AETHLON MEDICAL, INC.

                                                 By:_______________________
                                                 Name:_____________________
                                                 Title:____________________

                                       10
<PAGE>

                              WARRANT EXERCISE FORM
                              ---------------------

                                                       Date:______________, 200_

AETHLON MEDICAL, INC.
_____________
_____________
Attention:  ________________

Ladies and Gentlemen:

 The undersigned, being the registered holder of your Warrant for the purchase
of _______________ Warrant Shares issued ____________, 2005 accompanying this
letter, hereby irrevocably exercises such Warrant for ____________ shares of
Warrant Shares (as defined in said Warrant), and herewith makes payment therefor
[via "cash-less exercise"] in accordance with the Warrant, and requests that
such shares of Warrant Shares be issued in the name of, and delivered to FUSION
CAPITAL FUND II, LLC, at the address shown below the signature line hereof.

If said number of shares shall not be all the shares issuable upon exercise of
the attached Warrant, a new Warrant is to be issued in the name of the
undersigned for the balance remaining of such shares less any fraction of a
share paid in cash.

FUSION CAPITAL FUND II, LLC
BY: FUSION CAPITAL PARTNERS, LLC

By:_________________________
Name:
Title:

Fusion Capital Fund II, LLC
222 Merchandise Mart Plaza, Suite 9-112
Chicago, IL 60654

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00085-of-00352.parquet"}]]